Gilead Sciences (NASDAQ:GILD) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday, October 15th, BidAskClub reports.
Several other equities research analysts have also recently commented on GILD. Citigroup set a $78.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Maxim Group set a $84.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, July 31st. BMO Capital Markets set a $82.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Royal Bank of Canada raised Gilead Sciences from an “outperform” rating to a “top pick” rating and set a $91.00 price objective for the company in a research note on Monday, July 29th. Finally, Wells Fargo & Co raised Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $68.00 to $88.00 in a research note on Monday, July 15th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $79.27.
Shares of GILD traded up $1.42 during trading hours on Tuesday, hitting $65.38. 4,953,000 shares of the company were exchanged, compared to its average volume of 6,639,518. The firm’s fifty day moving average is $64.15 and its 200 day moving average is $65.25. Gilead Sciences has a fifty-two week low of $60.32 and a fifty-two week high of $72.90. The company has a market cap of $82.81 billion, a price-to-earnings ratio of 10.63, a P/E/G ratio of 3.47 and a beta of 1.09. The company has a quick ratio of 2.96, a current ratio of 3.06 and a debt-to-equity ratio of 1.13.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 EPS for the quarter, topping the consensus estimate of $1.74 by $0.01. Gilead Sciences had a return on equity of 37.50% and a net margin of 12.04%. The business had revenue of $5.60 billion during the quarter, compared to analysts’ expectations of $5.61 billion. During the same quarter last year, the firm posted $1.84 earnings per share. The firm’s revenue was up .1% on a year-over-year basis. Analysts anticipate that Gilead Sciences will post 6.66 EPS for the current year.
In related news, EVP Brett A. Pletcher sold 5,677 shares of Gilead Sciences stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $63.31, for a total transaction of $359,410.87. Following the transaction, the executive vice president now owns 21,521 shares of the company’s stock, valued at $1,362,494.51. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Brett A. Pletcher sold 608 shares of Gilead Sciences stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $64.35, for a total value of $39,124.80. Following the transaction, the executive vice president now directly owns 27,198 shares in the company, valued at approximately $1,750,191.30. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 17,288 shares of company stock worth $1,108,682. 0.20% of the stock is owned by insiders.
Large investors have recently made changes to their positions in the stock. Advisors Preferred LLC bought a new stake in Gilead Sciences during the second quarter worth $26,000. Weaver Consulting Group bought a new stake in Gilead Sciences during the first quarter worth $34,000. First Financial Corp IN lifted its holdings in Gilead Sciences by 286.4% during the third quarter. First Financial Corp IN now owns 541 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 401 shares during the period. Legacy Advisors LLC bought a new stake in Gilead Sciences during the second quarter worth $37,000. Finally, Venturi Wealth Management LLC bought a new stake in Gilead Sciences during the third quarter worth $40,000. 79.91% of the stock is currently owned by institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.